TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.

Eradication of smallpox and discontinuation of the vaccination campaign resulted in an increase in the percentage of unvaccinated individuals, highlighting the need for postexposure efficient countermeasures in case of accidental or deliberate viral release. Intranasal infection of mice with ectrome...

Full description

Bibliographic Details
Main Authors: Tomer Israely, Sharon Melamed, Hagit Achdout, Noam Erez, Boaz Politi, Trevor Waner, Shlomo Lustig, Nir Paran
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4211728?pdf=render
id doaj-72df6e9632784be587601a74bcbf824c
record_format Article
spelling doaj-72df6e9632784be587601a74bcbf824c2020-11-25T00:07:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e11054510.1371/journal.pone.0110545TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.Tomer IsraelySharon MelamedHagit AchdoutNoam ErezBoaz PolitiTrevor WanerShlomo LustigNir ParanEradication of smallpox and discontinuation of the vaccination campaign resulted in an increase in the percentage of unvaccinated individuals, highlighting the need for postexposure efficient countermeasures in case of accidental or deliberate viral release. Intranasal infection of mice with ectromelia virus (ECTV), a model for human smallpox, is curable by vaccination with a high vaccine dose given up to 3 days postexposure. To further extend this protective window and to reduce morbidity, mice were vaccinated postexposure with Vaccinia-Lister, the conventional smallpox vaccine or Modified Vaccinia Ankara, a highly attenuated vaccine in conjunction with TLR3 or TLR9 agonists. We show that co-administration of the TLR3 agonist poly(I:C) even 5 days postexposure conferred protection, avoiding the need to increase the vaccination dose. Efficacious treatments prevented death, ameliorated disease symptoms, reduced viral load and maintained tissue integrity of target organs. Protection was associated with significant elevation of serum IFNα and anti-vaccinia IgM antibodies, modulation of IFNγ response, and balanced activation of NK and T cells. TLR9 agonists (CpG ODNs) were less protective than the TLR3 agonist poly(I:C). We show that activation of type 1 IFN by poly(I:C) and protection is achievable even without co-vaccination, requiring sufficient amount of the viral antigens of the infective agent or the vaccine. This study demonstrated the therapeutic potential of postexposure immune modulation by TLR activation, allowing to alleviate the disease symptoms and to further extend the protective window of postexposure vaccination.http://europepmc.org/articles/PMC4211728?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Tomer Israely
Sharon Melamed
Hagit Achdout
Noam Erez
Boaz Politi
Trevor Waner
Shlomo Lustig
Nir Paran
spellingShingle Tomer Israely
Sharon Melamed
Hagit Achdout
Noam Erez
Boaz Politi
Trevor Waner
Shlomo Lustig
Nir Paran
TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
PLoS ONE
author_facet Tomer Israely
Sharon Melamed
Hagit Achdout
Noam Erez
Boaz Politi
Trevor Waner
Shlomo Lustig
Nir Paran
author_sort Tomer Israely
title TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
title_short TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
title_full TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
title_fullStr TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
title_full_unstemmed TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
title_sort tlr3 and tlr9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Eradication of smallpox and discontinuation of the vaccination campaign resulted in an increase in the percentage of unvaccinated individuals, highlighting the need for postexposure efficient countermeasures in case of accidental or deliberate viral release. Intranasal infection of mice with ectromelia virus (ECTV), a model for human smallpox, is curable by vaccination with a high vaccine dose given up to 3 days postexposure. To further extend this protective window and to reduce morbidity, mice were vaccinated postexposure with Vaccinia-Lister, the conventional smallpox vaccine or Modified Vaccinia Ankara, a highly attenuated vaccine in conjunction with TLR3 or TLR9 agonists. We show that co-administration of the TLR3 agonist poly(I:C) even 5 days postexposure conferred protection, avoiding the need to increase the vaccination dose. Efficacious treatments prevented death, ameliorated disease symptoms, reduced viral load and maintained tissue integrity of target organs. Protection was associated with significant elevation of serum IFNα and anti-vaccinia IgM antibodies, modulation of IFNγ response, and balanced activation of NK and T cells. TLR9 agonists (CpG ODNs) were less protective than the TLR3 agonist poly(I:C). We show that activation of type 1 IFN by poly(I:C) and protection is achievable even without co-vaccination, requiring sufficient amount of the viral antigens of the infective agent or the vaccine. This study demonstrated the therapeutic potential of postexposure immune modulation by TLR activation, allowing to alleviate the disease symptoms and to further extend the protective window of postexposure vaccination.
url http://europepmc.org/articles/PMC4211728?pdf=render
work_keys_str_mv AT tomerisraely tlr3andtlr9agonistsimprovepostexposurevaccinationefficacyoflivesmallpoxvaccines
AT sharonmelamed tlr3andtlr9agonistsimprovepostexposurevaccinationefficacyoflivesmallpoxvaccines
AT hagitachdout tlr3andtlr9agonistsimprovepostexposurevaccinationefficacyoflivesmallpoxvaccines
AT noamerez tlr3andtlr9agonistsimprovepostexposurevaccinationefficacyoflivesmallpoxvaccines
AT boazpoliti tlr3andtlr9agonistsimprovepostexposurevaccinationefficacyoflivesmallpoxvaccines
AT trevorwaner tlr3andtlr9agonistsimprovepostexposurevaccinationefficacyoflivesmallpoxvaccines
AT shlomolustig tlr3andtlr9agonistsimprovepostexposurevaccinationefficacyoflivesmallpoxvaccines
AT nirparan tlr3andtlr9agonistsimprovepostexposurevaccinationefficacyoflivesmallpoxvaccines
_version_ 1725418467307290624